Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Heidi Henson is Director at Lisata Therapeutics. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jan 13, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
2
1 buy, median −25.3 pts vs S&P 500, beat it 0 of 1 time.
Average −25.3 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Dec 6, 2024 to Dec 6, 2024, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Jan 9, 202630Kdisclosed Jan 13
DetailsOfficial recordDec 4, 2024Bought~$100Kdisclosed Dec 6
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
As of the latest filing on , Heidi Henson reported holding 85,725 shares of Lisata Therapeutics (LSTA), worth about $104K at the last close of $1 (Nov 13, 2026). Holdings are also on file at Perspective Therapeutics (CATX); together they are worth about $128K.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Lisata Therapeutics LSTA | 85,725 | 86K direct | $1 | $104K | Jan 9, 2026 |
| Perspective Therapeutics CATX | 25,975 | 26K revocable trust | $1 | $24K | Dec 4, 2024 |
Is this Heidi Henson’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Heidi Henson reported 1 open-market purchase and 0 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Jan 9, 2026, Heidi Henson reported holding 85,725 shares of Lisata Therapeutics (LSTA). At the last close of $1 on Nov 13, 2026, that is about $104K. This is the stake disclosed in filings, not a net worth.
Heidi Henson bought shares on the open market in 2024, and has not bought since 2024.
In SEC filings since 2024: the latest open-market purchase is from 2024; no open-market sale is on record.
Perspective Therapeutics (CATX), from 2024 to 2024: 1 purchase and 0 sales.
Heidi Henson bought shares on the open market in 2024, and has not bought since 2024.
Heidi Henson reported 1 open-market purchase and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $100K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
